Senti Biosciences Set to Shine at Healthcare Conference Taipei 2026

Senti Biosciences, Inc. (Nasdaq: SNTI), a pioneering player in the biotechnology sector, has announced that its Co-Founder and Chief Executive Officer, Dr. Timothy Lu, will deliver a presentation at the highly anticipated Healthcare Conference Taipei 2026. This event, organized in collaboration with J.P. Morgan, UC Berkeley, and the Regent Taipei, is scheduled to take place on February 10-11, 2026, at the Regent Taipei Hotel.

Dr. Lu's presentation is set for Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, and will take place in Track 1 at the Regent Ballroom (Level 3). The eight-minute talk aims to provide insights into Senti’s innovative Gene Circuit technology platform, highlighting the company’s pipeline progress and strategic priorities. Notably, the presentation will focus on potential partnership opportunities spanning investment, research and development, manufacturing, and clinical collaboration.

In a statement regarding the event, Dr. Lu expressed his enthusiasm about being selected for an on-stage presentation, emphasizing the importance of the conference in connecting with a global audience of investors and strategic partners. He stated, "We look forward to sharing how our Gene Circuit platform enables greater precision, control, and safety in cell and gene therapies, as well as discussing potential collaborations to advance transformative therapeutic programs for patients." This reflects Senti's commitment to advancing its innovative therapies and fostering collaborations that could accelerate their development.

Following the presentation, Senti’s management will engage in post-presentation networking during a scheduled break at the conference. Attendees can find them at Table #1 in the Level 3 foyer outside the Regent Ballroom, providing a valuable opportunity for direct interactions and discussions with the company’s leadership.

Senti Biosciences is at the forefront of developing next-generation cell and gene therapies aimed at treating patients with incurable diseases. Utilizing its proprietary synthetic biology platform, the company engineers Gene Circuits designed for enhanced precision and control in therapeutic applications. These Gene Circuits have shown promise in preclinical settings, effectively targeting cancer cells while sparing healthy tissues, thus increasing specificity and control even post-administration.

Senti's comprehensive pipeline includes engineered cell therapies aimed at addressing challenging liquid and solid tumor indications. Additionally, the potential breadth of their Gene Circuits extends beyond oncology, with ongoing advancements through strategic partnerships.

As Senti Biosciences prepares for its presentation at Healthcare Conference Taipei 2026, the event marks a significant moment for the company and its innovative Gene Circuit platform. With a focus on collaboration and transformative therapeutic solutions, Senti is poised to make a lasting impact in the biotechnology landscape. Investors and industry stakeholders are encouraged to keep a close watch on the developments emerging from this conference, as Senti continues to push the boundaries of what is possible in cell and gene therapy.